Last Updated: 13 Sep 2024
Executive Summary
Altimmune Inc. (ALT) is a clinical-stage biopharmaceutical company focused on developing intranasal vaccines, immunomodulatory therapies, and treatments for liver disease. The company has a market capitalization of $509.57 million and trades on the NASDAQ exchange. Altimmune's latest stock price is $7.1.
Company Overview
Altimmune was founded in 1998 and is headquartered in Gaithersburg, Maryland. The company's lead product candidate is NasoVAX, an intranasal COVID-19 vaccine. Altimmune is also developing other intranasal vaccines for respiratory syncytial virus (RSV) and influenza. The company's immunomodulatory therapies are designed to treat autoimmune diseases and cancer. Altimmune's treatment for liver disease is called ALT-803.
Fundamental Analysis
Altimmune's financial performance has been mixed in recent years. The company reported a net loss of $96.88 million in 2021, compared to a net loss of $75.19 million in 2020. Revenue increased from $235,000 in 2020 to $409,000 in 2021. Altimmune's gross profit margin was -172.4% in 2021, compared to -259.1% in 2020. The company's operating margin was -53.49% in 2021, compared to -42.31% in 2020. Altimmune's net loss per share was $1.63 in 2021, compared to a net loss per share of $1.25 in 2020.
Technical Analysis
Altimmune's stock price has been in a downtrend since early 2022. The stock is currently trading below its 50-day and 200-day moving averages. The relative strength index (RSI) is below 30, which indicates that the stock is oversold. The moving average convergence divergence (MACD) is also below zero, which indicates that the stock is in a downtrend.
Short Term Outlook
The short-term outlook for Altimmune is bearish. The stock is in a downtrend and is trading below its moving averages. The RSI and MACD indicators are also bearish.
Long Term Outlook
The long-term outlook for Altimmune is more positive. The company has a strong pipeline of products in development, including NasoVAX, which has the potential to be a blockbuster drug. Altimmune also has a strong balance sheet with $239.7 million in cash and equivalents.
Analyst Recommendations
Analysts are mixed on Altimmune. One analyst has a Strong Buy rating on the stock, five analysts have a Buy rating, two analysts have a Hold rating, and no analysts have a Sell or Strong Sell rating. The average analyst target price is $20.57.
